| Document |
Document Title |
|
JP2016517412A |
The present invention relates to the compound for FASN prevention, constituents, those composition, application, and an antidote. An example of the compound of the present invention is shown below. [Drawing 1]
|
|
JP2016106148A |
To administer lorcaserin to individuals with renal impairment.The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribin...
|
|
JP5934114B2 |
Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocr...
|
|
JP5931046B2 |
|
|
JP2016513112A |
Compounds are provided that include one or more subclass modulators of the vasopressin receptor, such as the positive allosteric modulators, piperazine, piperidine, spiro-furanopiperidine, and analogs thereof. The compound can be a selec...
|
|
JP5916793B2 |
Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.
|
|
JP2016047837A |
To provide a production method of an intermediate in the synthesis of ivabradine, salts thereof with a pharmaceutically acceptable acid and hydrates thereof.A synthesis process gains (2E)-3-(3,4-dimethoxy) prop-2-enenitrile shown in form...
|
|
JP5893085B2 |
The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is r...
|
|
JP5893083B2 |
This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X 1 is a halogen atom, R 1 and R 2 are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield a...
|
|
JP2016508521A |
A tricyclic chemical regulator of FOXO transcription factor proteins is disclosed. The compound is effective in treating tumors, age-onset protein toxicity, stress-induced depression, inflammation, and acne. The compounds belong to the f...
|
|
JP5878494B2 |
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ...
|
|
JP5875843B2 |
The present invention provides a method for producing a zeolite molded article having an excellent mechanical strength. The method for producing a zeolite molded article according to the present invention comprises the following steps (1...
|
|
JP5870937B2 |
[Problem] To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT 5A receptor regulating action. [Means for Solution] It was found that a tetrahydroisoquinoline derivative characterized...
|
|
JP5863757B2 |
Synthesizing 3-(2-bromo-4,5-dimethoxy-phenyl)propanenitrile (I) comprises subjecting 1-bromo-2-(bromomethyl)-4,5-dimethoxy-benzene (II) to the action of a base in the presence of acetonitrile in an organic solvent to yield (I). Synthesiz...
|
|
JP2016504419A |
The present invention relates to the process of producing 5-formylvaleric acid and adipic acid or an ester thereof from an isomer mixture of pentenic acid or an ester thereof, said mixture comprising at least 4-pentenoic acid or an ester...
|
|
JP2016503808A |
The present invention generally relates to a series of compounds, pharmaceutical compositions containing the compounds, and the compounds and their use as therapeutic agents. More specifically, the compound of the present invention is a ...
|
|
JPWO2013187406A1 |
An active ingredient of a pharmaceutical composition for preventing and / or treating pollakiuria, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, etc., which has an excellent operative effect on...
|
|
JP5847830B2 |
The present invention relates to lactam derivatives of formula (I) wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to ...
|
|
JP5848698B2 |
The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, centr...
|
|
JP5845283B2 |
wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, ...
|
|
JP5846909B2 |
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase ...
|
|
JP5843182B2 |
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I'), W, Y, R 2 , R 3 , R 4 , and Y 4 are as described hereinabove), or pharmaceu...
|
|
JP5842915B2 |
The invention provides a production method of a cycloalkanone oxime by photonitrosation method using, as the light source, light emitting diodes which are the light source for the next generation as a replacement for an electric discharg...
|
|
JP5837114B2 |
Synthesizing (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxyl
ic acid compound (I), comprises enantioselective enzymatic hydrolysis of 3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile
compounds (IV), using the ni...
|
|
JP5833535B2 |
|
|
JP2015216382A |
To provide a material for a luminescent element capable of producing an organic electroluminescent element having excellent luminous efficiency and excellent life time characteristics.The organic electroluminescent element includes a lum...
|
|
JP5827572B2 |
Provided is a method for manufacturing a zeolite by effectively using ammonia and/or an ammonium salt collected after a contact processing so that an aqueous solution containing ammonia and an ammonium salt can be repeatedly used. Disclo...
|
|
JP5821623B2 |
|
|
JP2015533149A |
The present invention relates to compounds of formula (I) (wherein Y, R1 and R3 are defined in the detailed description and claims), and pharmaceutically acceptable salts thereof. In addition, the present invention relates to a method fo...
|
|
JP2015532268A |
The present invention relates to a method for producing a metathesis product comprising contacting a metathesis starting material with a metathesis catalyst under metathesis conditions, wherein the metathesis catalyst is reduced to half ...
|
|
JP5798115B2 |
This invention provides compounds of formula (I) wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compou...
|
|
JP2015180635A |
To provide a method for producing caprolactam from ingredients obtained by a biochemical process.A method for preparing caprolactam comprises recovering a mixture containing 6-aminocaproic acid, from a culture medium comprising biomass, ...
|
|
JP5793171B2 |
Preparation of dimethoxyphenyl propanenitrile compound (I) involves reacting 3-(3,4-dimethoxyphenyl)propanenitrile with N-bromosuccinimide in the presence of an organic solvent. Preparation of dimethoxyphenyl propanenitrile compound of f...
|
|
JP2015174848A |
To provide a lactam purification method which efficiently reduces microgel in anhydrous lactam in which the microgel generates due to storage abnormality of hydrous lactam, supervisory oversight of an operation condition in dehydration d...
|
|
JP2015529250A |
Equation (I); [Chemical 98](I) (In the formula, R1Is -CH2CH2CF3Or-CH2CH2CH3Is; R2Is -CH2CH2CF3, -CH2CH2CH3, -CH2(Cyclopropyl), phenyl or [Chemical 99]Is; R3Is H; Ra, Rb b, Y, and z are defined herein). Also disclosed are methods of using...
|
|
JP2015172030A |
To provide a safe herbicide that has an effect on a variety of weeds at a low dosage, and alleviates problems such as soil contamination and an influence on succeeding crops.A herbicide comprises, for example, a haloalkylsulfonamide deri...
|
|
JP5782586B2 |
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especia...
|
|
JP5782503B2 |
Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits high luminous efficiency in blue color and excellent life property, i...
|
|
JP5781008B2 |
The present invention is a process for preparing crystalline form of ( R )-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate.
|
|
JP5776195B2 |
|
|
JP5776194B2 |
|
|
JP5777067B2 |
The invention relates to a method for preparing caprolactam comprising recovering a mixture containing 6-aminocaproic acid, from a culture medium comprising biomass, and thereafter cyclising the 6-aminocaproic acid in the presence of sup...
|
|
JP2015155471A |
To provide a composition and a method useful for the regulation of signal transduction mediated by Toll-like receptors TLR7 and / or TLR8. Compositions and methods useful for the regulation of signal transduction mediated by Toll-like re...
|
|
JP2015155472A |
To provide a composition and a method useful for the regulation of signal transduction mediated by Toll-like receptors TLR7 and / or TLR8. Compositions and methods useful for the regulation of signal transduction mediated by Toll-like re...
|
|
JP2015145401A |
To provide compounds for medicament to inhibit histone deacetylase.This invention provides a compound such as phenyl hydroxamic acid substituted with a group comprising, for example, oxazepine, diazepine, thiazepine skeletons, pyrimidine...
|
|
JP5764151B2 |
Preparing an optically pure (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxyl
ic acid compound (I), comprises enantioselective enzymatically esterifying a racemic acid or 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxyl...
|
|
JP2015522546A |
The present invention relates to inhibitors of the activity of the mitochondrial electron transport chain complex (III) and its use in the treatment and / or prevention of cancers that present tumor-initiating cells. The present inventio...
|
|
JP5756804B2 |
Provided are compounds of formula (I) useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compounds have use in treating or preventing oral cancer.
|
|
JP5756805B2 |
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, inf...
|
|
JP5749548B2 |
|
